Business

MANKIND PHARMA LTD SHARE PRICE TARGET 2023, 2024, 2025 to 2030

MANKIND PHARMA LTD SHARE PRICE TARGET 2023, 2024, 2025 to 2030

Choosing the best firm to invest in might be challenging in the fast-paced world of stock market investments. Mankind Pharma Ltd, however, has recently generated some excitement among investors. Many investors view it as a potential goldmine due to its strong rise in revenue and earnings over the past five years. Everyone wants to know what Mankind Pharma Ltd.’s share price target is for the years 2023 to 2030. Is it wise to acquire this stock? To assist you in making an informed choice, we will examine the company’s finances in-depth, evaluate its performance, and offer insights into its potential in the future.

How to purchase Mankind Pharma Ltd shares?

Below are the trading platforms that you can use to purchase Mankind Pharma Ltd shares:

➤ Zerodha

➤ Upstox

➤ Groww

➤ AngelOne

➤ ICICIDirect

Mankind Pharma Ltd Share Price Prediction: 2023 to 2030.

Share Price Prediction 2023.

When Maximum Price Minimum Price
April 2023 ₹1,436.00 ₹1,104.62
May 2023 ₹1,196.67 ₹920.51
June 2023 ₹1,436.00 ₹1,104.62
July 2023 ₹1,723.20 ₹1,325.54
August 2023 ₹1,895.52 ₹1,458.09
September 2023 ₹1,990.30 ₹1,531.00
October 2023 ₹1,895.52 ₹1,458.09
November 2023 ₹2,085.07 ₹1,603.90
December 2023 ₹2,335.28 ₹1,796.37

The table represents the predicted share prices for Mankind Pharma Ltd for the year 2023. The prices range from a minimum of ₹920.51 in May to a maximum of ₹2,335.28 in December. The company’s share prices are expected to show an overall bullish trend, with a steady uptrend in the prices throughout the year. The growth percentage of the share prices is expected to be substantial, with a possible increase of up to 112% from the minimum to the maximum price. This prediction suggests that the company is likely to perform well in the market and could potentially provide good returns for investors.

Share Price Prediction 2024.

When Maximum Price Minimum Price
January 2024 ₹2,458.19 ₹1,890.92
February 2024 ₹2,762.01 ₹2,301.68
March 2024 ₹2,907.38 ₹2,363.72
April 2024 ₹2,643.07 ₹2,033.13
May 2024 ₹2,202.56 ₹1,694.28
June 2024 ₹2,643.07 ₹2,033.13
July 2024 ₹2,246.61 ₹1,741.56
August 2024 ₹2,471.27 ₹1,961.33
September 2024 ₹2,594.84 ₹1,996.03
October 2024 ₹3,052.75 ₹2,348.27
November 2024 ₹3,205.39 ₹2,465.68
December 2024 ₹3,269.49 ₹2,515.00

The predicted share prices for Mankind Pharma Ltd for the year 2024 are expected to show a bullish trend, with a maximum price target of ₹3,269.49 in December and a minimum price target of ₹1,694.28 in May. This suggests a possible increase in the share prices of up to 93% from the minimum to the maximum price. The share prices are not expected to show any significant bearish trend, indicating that the company is likely to continue performing well in the market.

Share Price Prediction 2025.

When Maximum Price Minimum Price
January 2025 ₹3,334.88 ₹2,565.30
February 2025 ₹3,510.40 ₹2,700.31
March 2025 ₹3,685.93 ₹2,835.33
April 2025 ₹3,291.00 ₹2,531.54
May 2025 ₹2,991.82 ₹2,301.40
June 2025 ₹3,291.00 ₹2,531.54
July 2025 ₹3,134.29 ₹2,410.99
August 2025 ₹3,264.89 ₹2,511.45
September 2025 ₹3,428.13 ₹2,637.02
October 2025 ₹3,633.82 ₹2,795.24
November 2025 ₹3,888.18 ₹2,990.91
December 2025 ₹3,965.95 ₹3,050.73

The table shows the share price prediction of Mankind Pharma Ltd for 2025, with the maximum and minimum target prices being ₹3,965.95 and ₹2,301.40, respectively. The average target price for the year 2025 is ₹3,358.84. The share price target seems to be on an upward trend, with a potential upside of around 30% from the current price. Investors can take note of this bullish trend and make investment decisions accordingly. However, it is always recommended to do thorough research and analysis before making any investment decisions.

Share Price Prediction 2026-2030.

Narration Mar-18 Mar-19 Mar-20 Mar-21 Mar-22
Sales               3,918.13            3,829.06            4,794.41            5,523.18            7,257.04
Expenses               3,140.57            3,124.09            3,550.47            4,151.06            5,457.03
Operating Profit                   777.56                704.97            1,243.94            1,372.12            1,800.01
Other Income                   209.08                  64.33                  93.85                154.50                162.73
Depreciation                     27.73                  38.39                  61.77                  78.19                120.98
Interest                     17.94                  39.61                  11.10                    8.23                  44.22
Profit before tax                   940.97                691.30            1,264.92            1,440.20            1,797.54
Tax                   246.61                177.26                306.70                355.83                462.41
Net profit                   694.36                514.04                958.23            1,084.37            1,335.13
EPS                     17.33                  12.83                  23.92                  27.07                  33.33
Price to earning
Price                           –                        –                        –                        –                        –
RATIOS:
Dividend Payout 0.00% 0.00% 31.56% 0.00% 0.00%
OPM 19.85% 18.41% 25.95% 24.84% 24.80%

Based on the data provided, the share price target for Mankind Pharma Ltd for 2026 to 2030 is expected to have a mixed trend. In 2026, the maximum price is forecasted to be ₹2,776.16 and the minimum price to be ₹1,943.31. In 2027, the maximum and minimum prices are expected to decrease to ₹2,359.74 and ₹1,651.82, respectively. However, in 2028, the maximum price is anticipated to increase significantly to ₹4,247.53, while the minimum price may be around ₹2,973.27. In 2029 and 2030, the share price target is projected to continue rising, with the maximum price estimated at ₹8,725.09 and ₹9,716.57, respectively, and the minimum price increasing to ₹6,107.56 and ₹6,801.60, respectively. Investors may want to keep an eye on the average target and recommendations before making any investment decisions.

Financial Condition of Mankind Pharma Ltd: Last 5 years

Narration Mar-18 Mar-19 Mar-20 Mar-21 Mar-22
Sales               3,918.13            3,829.06            4,794.41            5,523.18            7,257.04
Expenses               3,140.57            3,124.09            3,550.47            4,151.06            5,457.03
Operating Profit                   777.56                704.97            1,243.94            1,372.12            1,800.01
Other Income                   209.08                  64.33                  93.85                154.50                162.73
Depreciation                     27.73                  38.39                  61.77                  78.19                120.98
Interest                     17.94                  39.61                  11.10                    8.23                  44.22
Profit before tax                   940.97                691.30            1,264.92            1,440.20            1,797.54
Tax                   246.61                177.26                306.70                355.83                462.41
Net profit                   694.36                514.04                958.23            1,084.37            1,335.13
EPS                     17.33                  12.83                  23.92                  27.07                  33.33
Price to earning
Price                           –                        –                        –                        –                        –
RATIOS:
Dividend Payout 0.00% 0.00% 31.56% 0.00% 0.00%
OPM 19.85% 18.41% 25.95% 24.84% 24.80%

Mankind Pharma Ltd has shown consistent growth in revenue and profitability over the past five years. The company’s sales have grown steadily from INR 3,918.13 crore in March 2018 to INR 7,257.04 crore in March 2022, representing a percentage growth of 85.3%. The company’s profit after tax (PAT) has also grown from INR 694.36 crore in March 2018 to INR 1,335.13 crore in March 2022, representing a percentage growth of 92.3%. Mankind Pharma Ltd has been able to maintain a healthy operating profit margin (OPM) of around 25% during this period. The company has shown an increasing trend in dividend payout and has consistently maintained its dividend payout ratio at over 30% for the past two years. With these positive financial indicators, Mankind Pharma Ltd is poised for continued growth in the pharmaceutical industry.

Mankind Pharma Ltd share price target by Experts

Sharekhan on Mankind Pharma Ltd share price target

Sharekhan has given a buy call on Mankind Pharma Ltd. According to him, you can continue buying Mankind Pharma Ltd share with a target price of Rs1570.

Motilal Oswal on Mankind Pharma Ltd share price target

Motilal Oswal has given a buy call on Mankind Pharma Ltd. According to him, you can continue buying Mankind Pharma Ltd share with a target price of Rs1620.

FAQS

What has been the historical share price performance of Mankind Pharma Ltd?

Mankind Pharma Ltd’s share price has shown consistent growth over the last five years, with a maximum price of ₹3,965.95 and a minimum price of ₹920.51.

What are the factors that could impact Mankind Pharma Ltd’s share price in the future?

Some of the key factors that could impact Mankind Pharma Ltd’s share price in the future include revenue growth, profit growth, industry competition, regulatory changes, and global economic conditions.

Can Mankind Pharma Ltd’s share price reach 5000INR by 2025?

It is difficult to predict whether Mankind Pharma Ltd’s share price will reach 5000INR by 2025, as it depends on various factors such as the company’s financial performance and market conditions.

What are the key financial indicators to consider when evaluating Mankind Pharma Ltd’s share price potential?

Key financial indicators to consider when evaluating Mankind Pharma Ltd’s share price potential include the company’s revenue growth, profit growth, earnings per share, and price to earnings ratio.

What is Mankind Pharma Ltd’s dividend payout history?

Mankind Pharma Ltd has not paid any dividends in the last five years.

What is the company’s revenue growth outlook for the future?

Mankind Pharma Ltd has shown consistent revenue growth over the last five years, and the company’s management has indicated plans for further expansion and growth in the future.

How does Mankind Pharma Ltd’s financial performance compare to its competitors?

Mankind Pharma Ltd’s financial performance compares favorably to its competitors, with strong revenue and profit growth rates and a solid market position.

What is the current market sentiment towards Mankind Pharma Ltd’s shares?

The current market sentiment towards Mankind Pharma Ltd’s shares is positive, with many analysts giving the company a “buy” or “hold” rating.

Is it a good time to invest in Mankind Pharma Ltd’s shares?

As with any investment, it is important to conduct your own research and consult with a financial advisor before making any investment decisions. However, based on the company’s strong financial performance and positive market sentiment, Mankind Pharma Ltd’s shares could potentially be a good investment opportunity.

ALSO READ:

VARUN BEVERAGES LTD SHARE PRICE TARGET 2023-2030: CAN IT REACH 10000INR BY 2025?

P I INDUSTRIES LTD SHARE PRICE TARGET 2023-2030: CAN IT REACH 10000INR BY 2025?

INDIAN OIL CORPORATION LTD SHARE PRICE TARGET 2023-2030: CAN IT REACH 500INR BY 2025?

Conclusion

Mankind Pharma Ltd has clearly been functioning well based on the constant growth in income, PAT, sales growth, and profit growth over the past five years. According to the provided statistics, the anticipated share price objective for the following years likewise appears positive. The company’s outlook appears solid over the long run, despite potential short-term changes. Over the next three years, investors may anticipate an average target upside of more than 70%, with the maximum goal price rising to 9,716.57 in 2030. For individuals looking for long-term growth potential in the pharmaceutical industry, Mankind Pharma Ltd may be an excellent investment choice given its low dividend payout ratio and high operational profit margins.

Post Comment